With enpatoran soon entering Phase III clinical trials, the Phase II safety and efficacy results support the drug’s development.
Significant improvements in pain, function and patient global outcomes demonstrated LEVI-04 well tolerated and exhibits a favourable safety ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data March ...
TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of ...
Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Discov. 23, 656–657; 2024). With ...
OASIS+ is a suite of six multiple-award, indefinite-delivery/indefinite-quantity contracts with a five-year base period and a five-year option term. The contract ...
The General Services Administration has launched the second phase of the One Acquisition Solution for Integrated Services Plus, or OASIS+, contract program, adding five new service domains as part of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results